Western Standard Partners L.P. is Director at MERRIMACK PHARMACEUTICALS INC (MACK). They have made 6 open-market trades across 1 company since 2020, most recently 2023-11-17.
CIK 0001450414
6 open-market purchases totalling $2.3M since 2020, never a sale. Across 6 scored buys the stock is up 0.3% at ninety days, and 8.1 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| MACK | 459,792 | $7.0M |
Shares reported on the most recent Form 4, priced at the 2023-11-20 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 50% | 50% |
| Avg Move | +0.2% | -3.6% | +0.3% |
| Alpha | -1.2% | -5.7% | -8.1% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MACK | BUY | 2023-11-17 | 2023-11-20 | $12.50 | $4K | +1.6% | +2.4% | +15.7% |
| MACK | BUY | 2023-11-14 | 2023-11-16 | $12.50 | $1.3M | -0.6% | +2.2% | +14.6% |
| MACK | BUY | 2023-01-27 | 2023-01-31 | $11.40 | $249K | +0.5% | -0.5% | +6.8% |
| MACK | BUY | 2021-04-14 | 2021-04-16 | $6.63 | $584K | +5.2% | -13.9% | -13.9% |
| MACK | BUY | 2021-04-13 | 2021-04-15 | $6.26 | $124K | +8.1% | -12.1% | -14.6% |
| MACK | BUY | 2020-04-03 | 2020-04-07 | $2.74 | $46K | -13.5% | +0.5% | -6.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.